Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Invitae

Invitae's Court-Approved Bankruptcy Sale Set for Five Months

Invitae, a leading medical genetics company, has received court approval for a five-month bankruptcy sale. The sale process will allow Invitae to repay its...

Top News

12 Lousy Stocks Knock Cathie Wood Out Of The Top 10

Just like that, Cathie Wood's ARK Innovation ETF plunged out of the top 10 — actually the top 15 ETFs this year.

Investors Business Daily

Cathie Wood Buys Millions of Shares of a Struggling Stock

Ark Invest is embracing biotechnology.

The Street

From analysis to the latest developments in health,
read the most diverse news in one place.

Vital medical tests evade regulation

Money and lobbying help shield lab-developed tests, including prenatal screenings, from heightened federal scrutiny

Salon

Can Invitae Deliver a Positive Surprise?

A streamlined business could reach certain milestones faster than expected.

The Street

Would Exact Sciences Acquire Invitae? Unlikely.

Social media is speculating about the idea that Exact Sciences would buy Invitae. Investors should pinch themselves out of the daydream.

The Street

Meme-Stock Mania Is Leaving These Genomics Stocks

A handful of biotech stocks were catapulted higher by short squeezes. Whether they will recover their losses is an open question.

The Street

Read news from The Economist, FT, and more,
with one subscription

The Best ETF You Can Buy Makes A Complete Mockery Of Cathie Wood

A tough market for S&P 500 stocks tends to make a mockery of most investors. And Cathie Wood is no exception.

Investors Business Daily

Exact Sciences: Don't Deem It Guilty by Association

Genetic-testing stocks, especially those championed by asset manager Cathie Wood, have been pummeled. It's important to differentiate.

The Street

Fulgent Genetics Seeks Post-Pandemic Growth

The genetic testing company was an afterthought before the pandemic. Can it leverage newfound riches for long-term success?

The Street

This Unpopular Move Could Save Invitae

Offloading a recent acquisition could accelerate the path to profitability – or an acquisition.

The Street

Unusual Options Activity in FUBO: 2700% In 1 Day?!

Inside FUBO's under the radar rally, and the unusual options activity that preceded the short squeeze.

The Street

Invitae Goes Full Meme Stock. What's Next?

Shares of the genetic testing company have more than doubled in less than a week. It likely isn't durable.

The Street

What's Next for Invitae?

A painful (but necessary) restructuring is underway. Will the genomics stock regain the trust of investors soon?

The Street

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For July 26, 2022

Upgrades

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For July 21, 2022

Upgrades

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For July 19, 2022

Upgrades

The Street

3 Biotech Stocks That May Take Awhile to Recoup

How many years of future revenue and earnings were investors paying for in 2021? In some cases, quite a few.

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For June 3, 2022

Benzinga

Analyst Ratings for Invitae

Within the last quarter, Invitae (NYSE:NVTA) has observed the following analyst ratings:

The Street

Why I Sold My Invitae Stock

The genetic testing company has been unprofitable as it spent heavily (but that's only part of the story).

Benzinga

Invitae Earnings Perspective: Return On Capital Employed

According to Benzinga Pro data, during Q1, Invitae (NYSE:NVTA) posted sales of $123.69 million. Earnings were up 11.34%, but Invitae still reported an overall loss of $181.86 million.

Benzinga

Analyst Ratings for Invitae

Analysts have provided the following ratings for Invitae (NYSE:NVTA) within the last quarter:

StockNews.com

Is Invitae Stock a Buy Under $5?

Invitae's (NVTA) significant revenue growth in its most recently reported quarter and its success in bringing customized health monitoring into the mainstream have heightened investor optimism around the stock. However, given the company's widening losses and poor profitability, the question is, is it worth betting on the stock at the…

Benzinga

Recap: Invitae Q1 Earnings

Invitae (NYSE:NVTA) reported its Q1 earnings results on Tuesday, May 3, 2022 at 04:05 PM. Here's what investors need to know about the announcement. Earnings Invitae missed estimated earnings by 2.63%, reporting an EPS of $-0.78 versus an estimate of $-0.76.

1 2

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

SP Global Market Intelligence

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.